首页 | 本学科首页   官方微博 | 高级检索  
     

结直肠癌腹膜转移的治疗:新事实、新知识和新未来
引用本文:Ignace de Hingh. 结直肠癌腹膜转移的治疗:新事实、新知识和新未来[J]. 中国肿瘤临床, 2022, 49(24): 1308-1312. DOI: 10.12354/j.issn.1000-8179.2022.20220903
作者姓名:Ignace de Hingh
作者单位:荷兰埃因霍温卡特里娜癌症研究所外科
摘    要:结直肠癌腹膜转移(colorectal cancer peritoneal metastasis,CRCPM)一直是荷兰临床肿瘤学研究的重点领域之一,对比系统化疗加姑息手术治疗,CRCPM患者更易从肿瘤细胞减灭术(cytoreductive surgery,CRS)加腹腔热灌注化疗(hyperthermic intraperitoneal chemotherapy,HIPEC)中获益,CRS+HIPEC在治疗CRCPM中已具有稳定的临床基础。目前,荷兰建立了全国肿瘤登记处,对所有腹膜癌病例进行详细登记和分析。本文重点介绍了荷兰CRCPM最新研究,包括流行病学研究、多中心随机临床试验、基础和转化研究的新成果,给出了国际热点问题和学术争鸣的荷兰答案,提出了腹膜肿瘤学未来发展的新机遇和新方向。 

关 键 词:结直肠癌   腹膜转移   肿瘤细胞减灭术   腹腔热灌注化疗   临床试验   转化研究   精准医学
收稿时间:2022-06-13

Treatment of colorectal peritoneal metastasis: new facts,new knowledge,and new future
Affiliation:Department of Surgery, Catharina Cancer Institute, Eindhoven, The Netherlands
Abstract:Management of colorectal cancer peritoneal metastasis (CRCPM) has long been one of the key areas in clinical oncology of The Netherlands. compared with the palliative surgery plus systemic chemotherapy, the CRCPM patients were better treated with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC). Since then, the high-level clinical evidence has laid the foundation for adopting CRS+HIPEC to treat CRCPM. The Dutch National Cancer Registry has been established and regularly updated through the sustained efforts and detailed information on PM from various primary malignancies is available for academic research. This paper presented the most recent studies in CRCPM, including epidemiology research, multicenter randomized clinical trials, basic and translational researches, the Dutch answers to the recent hot topics and international debates. The new opportunities and new directions for the future are also highlighted. 
Keywords:
点击此处可从《中国肿瘤临床》浏览原始摘要信息
点击此处可从《中国肿瘤临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号